These findings identify MMP13 as a key protease elevated in DCIS progression, and implicate the integrin β6-fibronectin-MMP13 axis in the pro-tumourigenic properties of DCIS myoepithelial cells. Here, MMP13 is linked to ductal breast carcinoma in situ.